The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 05, 2022

Filed:

Oct. 11, 2019
Applicant:

Xencor, Inc., Monrovia, CA (US);

Inventors:

Matthew Bernett, Monrovia, CA (US);

John R. Desjarlais, Pasadena, CA (US);

Michael Hedvat, Encino, CA (US);

Suzanne Schubbert, Long Beach, CA (US);

Christine Bonzon, Los Angeles, CA (US);

Rumana Rashid, Temple City, CA (US);

Rajat Varma, Bethesda, MD (US);

Assignee:

Xencor, Inc., Monrovia, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); C07K 14/28 (2006.01); C12N 15/63 (2006.01); C07K 14/54 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/5443 (2013.01); A61K 39/395 (2013.01); C07K 16/2818 (2013.01); C12N 15/63 (2013.01); A61K 38/00 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/53 (2013.01); C07K 2319/30 (2013.01);
Abstract

The present invention is directed to novel PD-1 targeted heterodimeric Fc fusion proteins comprising an IL-15/IL-15Rα Fc-fusion protein and a PD-1 antibody fragment-Fc fusion protein. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered to a patient to treat cancer. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins are administered in combination with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab. In some embodiments, the PD-1 targeted IL-15/Rα-Fc fusion proteins do not compete with a PD-1 blockade antibody such as nivolumab and/or pembrolizumab for antigen binding.


Find Patent Forward Citations

Loading…